| 摘要 |
A compound represented by formula (1-1) or (1-2), or a pharmacologically acceptable salt thereof retains a principal therapeutic effect of sitaxentan and has an improved CYP inhibitory effect.
wherein R 1 is a halogen atom, etc., R 2 is a methyl group, etc., R 3 is a C 1-6 alkyl group, etc., and M is a group represented by:
etc. |
